206 related articles for article (PubMed ID: 34021685)
1. Characterizing the molecular and immune landscape of canine bladder cancer.
Cronise KE; Das S; Hernandez BG; Regan DP; Dailey DD; McGeachan RI; Lana SE; Page RL; Gustafson DL; Duval DL
Vet Comp Oncol; 2022 Mar; 20(1):69-81. PubMed ID: 34021685
[TBL] [Abstract][Full Text] [Related]
2. Identifying the ErbB/MAPK Signaling Cascade as a Therapeutic Target in Canine Bladder Cancer.
Cronise KE; Hernandez BG; Gustafson DL; Duval DL
Mol Pharmacol; 2019 Jul; 96(1):36-46. PubMed ID: 31048548
[TBL] [Abstract][Full Text] [Related]
3. [Diagnostic value of the BRAF variant V595E in urine samples, smears and biopsies from canine transitional cell carcinoma].
Aupperle-Lellbach H; Grassinger J; Hohloch C; Kehl A; Pantke P
Tierarztl Prax Ausg K Kleintiere Heimtiere; 2018 Oct; 46(5):289-295. PubMed ID: 30541168
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of epithelial and mesenchymal cell markers in canine urinary bladder transitional cell carcinoma.
Shinada M; Saeki K; Yoshitake R; Eto S; Tsuboi M; Chambers JK; Uchida K; Kato D; Yoshimoto S; Kamoto S; Ikeda N; Kinoshita R; Fujita N; Nishimura R; Nakagawa T
Vet J; 2020 Dec; 266():105571. PubMed ID: 33323173
[TBL] [Abstract][Full Text] [Related]
5. RNAseq expression patterns of canine invasive urothelial carcinoma reveal two distinct tumor clusters and shared regions of dysregulation with human bladder tumors.
Parker HG; Dhawan D; Harris AC; Ramos-Vara JA; Davis BW; Knapp DW; Ostrander EA
BMC Cancer; 2020 Mar; 20(1):251. PubMed ID: 32209086
[TBL] [Abstract][Full Text] [Related]
6. Effective detection of BRAF
Aeschlimann L; Kehl A; Guscetti F; Posthaus C; Aupperle-Lellbach H; Rottenberg S; de Brot S
Vet Comp Oncol; 2024 Jun; 22(2):295-302. PubMed ID: 38659202
[TBL] [Abstract][Full Text] [Related]
7. BRAF
Maeda S; Yoshitake R; Chambers JK; Uchida K; Eto S; Ikeda N; Nakagawa T; Nishimura R; Goto-Koshino Y; Yonezawa T; Momoi Y
Vet Pathol; 2021 Sep; 58(5):971-980. PubMed ID: 33205710
[TBL] [Abstract][Full Text] [Related]
8. Management of transitional cell carcinoma of the urinary bladder in dogs: a review.
Fulkerson CM; Knapp DW
Vet J; 2015 Aug; 205(2):217-25. PubMed ID: 25747698
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib inhibits tumor cell growth and angiogenesis in canine transitional cell carcinoma.
Yokota S; Yonezawa T; Momoi Y; Maeda S
J Vet Med Sci; 2022 May; 84(5):666-674. PubMed ID: 35387955
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of HER-2 via immunohistochemistry in canine urinary bladder transitional cell carcinoma - A marker of malignancy and possible therapeutic target.
Millanta F; Impellizeri J; McSherry L; Rocchigiani G; Aurisicchio L; Lubas G
Vet Comp Oncol; 2018 Jun; 16(2):297-300. PubMed ID: 28871659
[TBL] [Abstract][Full Text] [Related]
11. Naturally-occurring canine invasive urothelial carcinoma harbors luminal and basal transcriptional subtypes found in human muscle invasive bladder cancer.
Dhawan D; Hahn NM; Ramos-Vara JA; Knapp DW
PLoS Genet; 2018 Aug; 14(8):e1007571. PubMed ID: 30089113
[TBL] [Abstract][Full Text] [Related]
12. Expression of cell cycle regulators, 14-3-3σ and p53 proteins, and vimentin in canine transitional cell carcinoma of the urinary bladder.
Suárez-Bonnet A; Herráez P; Aguirre M; Suárez-Bonnet E; Andrada M; Rodríguez F; Espinosa de Los Monteros A
Urol Oncol; 2015 Jul; 33(7):332.e1-7. PubMed ID: 25979650
[TBL] [Abstract][Full Text] [Related]
13. BRAF mutation status and its prognostic significance in 79 canine urothelial carcinomas: A retrospective study (2006-2019).
Gedon J; Kehl A; Aupperle-Lellbach H; von Bomhard W; Schmidt JM
Vet Comp Oncol; 2022 Jun; 20(2):449-457. PubMed ID: 34878687
[TBL] [Abstract][Full Text] [Related]
14. Whole exome sequencing analysis of canine urothelial carcinomas without BRAF V595E mutation: Short in-frame deletions in BRAF and MAP2K1 suggest alternative mechanisms for MAPK pathway disruption.
Thomas R; Wiley CA; Droste EL; Robertson J; Inman BA; Breen M
PLoS Genet; 2023 Apr; 19(4):e1010575. PubMed ID: 37079639
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical detection of uroplakin III, cytokeratin 7, and cytokeratin 20 in canine urothelial tumors.
Ramos-Vara JA; Miller MA; Boucher M; Roudabush A; Johnson GC
Vet Pathol; 2003 Jan; 40(1):55-62. PubMed ID: 12627713
[TBL] [Abstract][Full Text] [Related]
16. Identification of survivin, an inhibitor of apoptosis, in canine urinary bladder transitional cell carcinoma.
Rankin WV; Henry CJ; Turnquist SE; Turk JR; Beissenherz ME; Tyler JW; Rucker EB; Knapp DW; Rodriguez CO; Green JA
Vet Comp Oncol; 2008 Sep; 6(3):141-50. PubMed ID: 19178674
[TBL] [Abstract][Full Text] [Related]
17. Flow cytometric DNA ploidy analysis in canine transitional cell carcinoma of urinary bladders.
Clemo FA; DeNicola DB; Carlton WW; Morrison WB; Walker E
Vet Pathol; 1994 Mar; 31(2):207-15. PubMed ID: 8203084
[TBL] [Abstract][Full Text] [Related]
18. Lipoxygenase-5 Expression in Canine Urinary Bladder: Normal Urothelium, Cystitis and Transitional Cell Carcinoma.
Finotello R; Schiavo L; Ressel L; Frohmader A; Silvestrini P; Verin R
J Comp Pathol; 2019 Jul; 170():1-9. PubMed ID: 31375151
[TBL] [Abstract][Full Text] [Related]
19. Establishment of Canine Transitional Cell Carcinoma Cell Lines Harboring BRAF V595E Mutation as a Therapeutic Target.
Jung H; Bae K; Lee JY; Kim JH; Han HJ; Yoon HY; Yoon KA
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502061
[TBL] [Abstract][Full Text] [Related]
20. Prognostic role of ΔNp63 expression in canine transitional cell carcinoma of the urinary bladder.
Nishimori T; Hanazono K; Matsuda K; Kawamura Y; Kadosawa T; Endo Y; Uchide T
Open Vet J; 2021; 11(4):700-706. PubMed ID: 35070867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
